A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma

Clinical Chemistry

Volumn 46, Issue 12, 2000, Pages 1946-1955

  Karpati, L ^a   Penke, B ^a   Katona, E ^a   Balogh, I ^a   Vamosi, G ^a   Muszbek, L ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CALCIUM ION; ENZYME PRECURSOR; TETRAPEPTIDE; THROMBIN;

ADULT; AGED; ARTICLE; ASSAY; BLOOD CLOTTING; FEMALE; HEMOPHILIA A; HUMAN; MALE; NORMAL HUMAN; PHOTOMETRY; POLYMERIZATION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REACTION ANALYSIS;

EID: 0033636292     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.12.1946     Document Type: Article

References (42)

1. Blood coagulation factor XIII: Structure and function
2. Mechanism and basis for specificity of transglutaminase catalyzed ε-(γ-glutamyl) lysine bond formation
3. Transglutaminases
4. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation and function
5. Human factor XIII: Fibrin-stabilizing factor
6. Factor XIII: Inherited and acquired deficiency
7. Alterations of haemostasis parameters with special reference to fibrin stabilization, factor XIII and fibronectin in patients with obliterative atherosclerosis
8. Plasma factor XIII and some other haemostasis parameters in patients with diabetic angiopathy
9. Factor XIII of blood coagulation in malignant hematological diseases
10. Deficiency in the A subunit of human coagulation factor XIII: Two novel point mutations demonstrate different effects on transcript levels
11. Association of a common polymorphism in the factor XIII gene with myocardial infarction
12. Association of FXIII Va134Leu with decreased risk of myocardial infarction in Finnish males
13. The association between the Va134Leu polymorphism in the factor XIII gene and brain infarction
14. Kinetic determination of blood coagulation factor XIII in plasma
15. A photometric assay for blood coagulation factor XIII
16. Optimisation of a new continuous UV assay for the determination of blood coagulation factor XIII activity in human plasma
17. Simultaneous purification of bovine prothrombin and factor X
18. Factor XIII (fibrin-stabilizing factor)
19. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences
20. Solid phase synthesis
21. 2)
22. Va134Leu polymorphism of plasma factor XIII: Biochemistry and epidemiology in familial thrombophilia
23. Processing data for outliers
24. Influence of statistical method used on the resulting estimate of normal range
25. On dividing reference data into subgroups to produce separate reference ranges
26. Evaluation of regression procedures for methods comparison studies
27. Estimation of the linear relationship between the measurements of two methods with proportional errors
28. Statistical methods for assessing agreement between two methods of clinical measurement
29. Effect of Va134Leu polymorphism on the activation of the coagulation factor XIII-A
30. Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation
31. Factor XIII assay by an isotope method
32. A filter paper assay for transamidating enzymes using radioactive amine substrates
33. Colorimetric assay of blood coagulation factor XIII in plasma
34. A microtiter assay for factor XIII using fibrinogen and biotinylcadaverne as substrates
35. 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor
36. 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilising factor
37. 2-Plasmin inhibitor is a substrate for tissue transglutaminase: An in vitro study
38. The Va134Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity
39. Genotype/phenotype correlations for coagulation factor XIII: Specific normal polymorphisms are associated with higher or low factor XIII specific activity